These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

340 related items for PubMed ID: 33960703

  • 1. Real-world utility of next-generation sequencing for targeted gene analysis and its application to treatment in lung adenocarcinoma.
    Kim JH, Yoon S, Lee DH, Jang SJ, Chun SM, Kim SW.
    Cancer Med; 2021 May; 10(10):3197-3204. PubMed ID: 33960703
    [Abstract] [Full Text] [Related]

  • 2. Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis.
    Tan AC, Lai GGY, Tan GS, Poon SY, Doble B, Lim TH, Aung ZW, Takano A, Tan WL, Ang MK, Tan BS, Devanand A, Too CW, Gogna A, Ong BH, Koh TPT, Kanesvaran R, Ng QS, Jain A, Rajasekaran T, Lim AST, Lim WT, Toh CK, Tan EH, Lim TKH, Tan DSW.
    Lung Cancer; 2020 Jan; 139():207-215. PubMed ID: 31835042
    [Abstract] [Full Text] [Related]

  • 3. Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests.
    Byeon S, Lee B, Park WY, Choi YL, Jung HA, Sun JM, Ahn JS, Ahn MJ, Park K, Lee SH.
    Clin Lung Cancer; 2020 May; 21(3):e182-e190. PubMed ID: 31839532
    [Abstract] [Full Text] [Related]

  • 4. Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma.
    Han JY, Kim SH, Lee YS, Lee SY, Hwang JA, Kim JY, Yoon SJ, Lee GK.
    Lung Cancer; 2014 Aug; 85(2):161-7. PubMed ID: 24857785
    [Abstract] [Full Text] [Related]

  • 5. Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negative.
    Lim SM, Kim EY, Kim HR, Ali SM, Greenbowe JR, Shim HS, Chang H, Lim S, Paik S, Cho BC.
    Oncotarget; 2016 Apr 26; 7(17):24172-8. PubMed ID: 26992220
    [Abstract] [Full Text] [Related]

  • 6. Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches.
    Drilon A, Wang L, Arcila ME, Balasubramanian S, Greenbowe JR, Ross JS, Stephens P, Lipson D, Miller VA, Kris MG, Ladanyi M, Rizvi NA.
    Clin Cancer Res; 2015 Aug 15; 21(16):3631-9. PubMed ID: 25567908
    [Abstract] [Full Text] [Related]

  • 7. Genetic Profiling of Non-Small Cell Lung Cancer in Moroccan Patients by Targeted Next-Generation Sequencing.
    El Zaitouni S, Laraqui A, Ghaouti M, Benzekri A, Kettani F, Boustany Y, Benmokhtar S, Lamrani Alaoui H, El Annaz H, Abi R, Tagajdid MR, El Kochri S, El Mchichi B, Bouaiti EA, Lahlou IA, El Hassani RA, Ennibi K.
    Technol Cancer Res Treat; 2024 Aug 15; 23():15330338241288907. PubMed ID: 39363851
    [Abstract] [Full Text] [Related]

  • 8. Clinical Impact of Hybrid Capture-Based Next-Generation Sequencing on Changes in Treatment Decisions in Lung Cancer.
    Rozenblum AB, Ilouze M, Dudnik E, Dvir A, Soussan-Gutman L, Geva S, Peled N.
    J Thorac Oncol; 2017 Feb 15; 12(2):258-268. PubMed ID: 27865871
    [Abstract] [Full Text] [Related]

  • 9. Prognostic value and therapeutic implications of expanded molecular testing for resected early stage lung adenocarcinoma.
    Kneuertz PJ, Carbone DP, D'Souza DM, Shilo K, Abdel-Rasoul M, Zhao W, Williams TM, Jones D, Merritt RE.
    Lung Cancer; 2020 May 15; 143():60-66. PubMed ID: 32208298
    [Abstract] [Full Text] [Related]

  • 10. Frequently used quantitative polymerase chain reaction-based methods overlook potential clinically relevant genetic alterations in epidermal growth factor receptor compared with next-generation sequencing: a retrospective clinical comparison of 1839 lung adenocarcinomas.
    Tønnesen E, Lade-Keller J, Stougaard M.
    Hum Pathol; 2021 Sep 15; 115():67-75. PubMed ID: 34153308
    [Abstract] [Full Text] [Related]

  • 11. Mutation Profile Assessed by Next-Generation Sequencing (NGS) of Circulating Tumor DNA (ctDNA) in Chinese Lung Adenocarcinoma Patients: Analysis of Real-World Data.
    Zhao S, Cong X, Liu Z.
    Biomed Res Int; 2021 Sep 15; 2021():8817898. PubMed ID: 33997043
    [Abstract] [Full Text] [Related]

  • 12. Molecular characterization of lung adenocarcinoma from Korean patients using next generation sequencing.
    Chun YJ, Choi JW, Hong MH, Jung D, Son H, Cho EK, Min YJ, Kim SW, Park K, Lee SS, Kim S, Kim HR, Cho BC, Korean Lung Cancer Consortium (KLCC).
    PLoS One; 2019 Sep 15; 14(11):e0224379. PubMed ID: 31765373
    [Abstract] [Full Text] [Related]

  • 13. Next generation sequencing in lung cancer: An initial experience from India.
    Gupta P, Saha K, Vinarkar S, Banerjee S, Choudhury SS, Parihar M, Midha D, Mukherjee G, Lingegowda D, Chatterjee S, ArunsinghS M, Shrimali R, Ganguly S, Dabkara D, Biswas B, Mishra DK, Arora N.
    Curr Probl Cancer; 2020 Jun 15; 44(3):100562. PubMed ID: 32178863
    [Abstract] [Full Text] [Related]

  • 14. Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21.
    Yu JY, Yu SF, Wang SH, Bai H, Zhao J, An TT, Duan JC, Wang J.
    Chin J Cancer; 2016 Mar 21; 35():30. PubMed ID: 27001083
    [Abstract] [Full Text] [Related]

  • 15. Global prognostic impact of driver genetic alterations in patients with lung adenocarcinoma: a real-life study.
    Paliogiannis P, Colombino M, Sini MC, Manca A, Casula M, Palomba G, Pisano M, Doneddu V, Zinellu A, Santeufemia D, Sardinian Lung Cancer (SLC) Study Group, Sotgiu G, Cossu A, Palmieri G.
    BMC Pulm Med; 2022 Jan 10; 22(1):32. PubMed ID: 35012520
    [Abstract] [Full Text] [Related]

  • 16. Mutation Profile of Resected EGFR-Mutated Lung Adenocarcinoma by Next-Generation Sequencing.
    Zhao ZR, Lin YB, Ng CSH, Zhang R, Wu X, Ou Q, Chen W, Zhou WJ, Lin YB, Su XD, Shao YW, Long H.
    Oncologist; 2019 Oct 10; 24(10):1368-1374. PubMed ID: 30872465
    [Abstract] [Full Text] [Related]

  • 17. Molecular diagnostic characteristics based on the next generation sequencing in lung cancer and its relationship with the expression of PD-L1.
    Liu J, Liu Y.
    Pathol Res Pract; 2020 Feb 10; 216(2):152797. PubMed ID: 31926773
    [Abstract] [Full Text] [Related]

  • 18. Comparison of next generation sequencing, SNaPshot assay and real-time polymerase chain reaction for lung adenocarcinoma EGFR mutation assessment.
    Cernomaz AT, Macovei II, Pavel I, Grigoriu C, Marinca M, Baty F, Peter S, Zonda R, Brutsche M, Grigoriu B.
    BMC Pulm Med; 2016 May 23; 16(1):88. PubMed ID: 27215400
    [Abstract] [Full Text] [Related]

  • 19. Epidermal growth factor receptor mutation status in pulmonary adenocarcinoma: Multi-institutional data discussion at national conference of "Lung Cancer Management in Indian context".
    Nakra T, Mehta A, Bal A, Nambirajan A, Mishra D, Midha D, Gupta N, Arora N, Gupta P, Gupta P, Singh V, Jain D.
    Curr Probl Cancer; 2020 Jun 23; 44(3):100561. PubMed ID: 32169258
    [Abstract] [Full Text] [Related]

  • 20. Next-generation sequencing informs diagnosis and identifies unexpected therapeutic targets in lung squamous cell carcinomas.
    Sands JM, Nguyen T, Shivdasani P, Sacher AG, Cheng ML, Alden RS, Jänne PA, Kuo FC, Oxnard GR, Sholl LM.
    Lung Cancer; 2020 Feb 23; 140():35-41. PubMed ID: 31855703
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.